Posts

GSK's $700M Alector Partnership Ends After Nivisnebart Alzheimer's Drug Fails Phase 2 Trial

on

Eli Lilly Touts Strong Early Launch of Foundayo Obesity Pill Despite Lagging Behind Novo's GLP-1

on

Bristol Myers Squibb's Pipeline Focus in Pivotal 2026

on

Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

BeOne Medicines Signs $2B Deal for Preclinical Trispecific Antibody Option with China's Huahui Health

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

Novartis CEO Calls for 'Complete Rethink' on Europe's Drug Pricing Policies

on

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for World's First AI-Driven Direct-to-Lung Clinical Study

on

Biogen's Post-Apellis Strategy: Expanding Early-Stage Pipeline to Drive Next-Generation Growth

on

AbbVie Reports Strong Skyrizi Sales Amid Wall Street Concerns Over J&J's Icotyde Pill

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Biopharma Bites: AstraZeneca's Camizestrant Faces FDA ODAC Scrutiny Amid Trial Design Concerns

on

AstraZeneca Posts 20% Jump in Cancer Drug Sales Amid Pipeline Challenges

on

Acrobat Genomics Advances to Next Phase of AI-Powered Inhibitor Discovery Program

on

Pharmatech Associates Appoints Erika Porcelli as CEO

on

Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion to Expand Rare Disease Portfolio

on

FDA's Oncologic Drugs Advisory Committee to Review AstraZeneca's Cancer Drugs in First Meeting in 9 Months

on

GSK CEO Luke Miels' First Quarter Results: Shingrix Surge Offsets Exdensur Pipeline Challenges

on

Incyte Scores Phase 3 Wins for Povorcitinib in Vitiligo Treatment

on

FDA Announces Real-Time Clinical Trial Data Review Initiative with AstraZeneca and Amgen Pilots

on

Hemab Therapeutics Holdings Sets Terms for $200 Million IPO

on

Spotlight On: Key Takeaways from Novartis' Q1 2026 Earnings Call

on

Abbott Receives FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered Coronary Imaging Platform

on

NervGen Pharma Appoints Keith Vendola as Chief Financial Officer

on

Novartis Stands by $5B Pluvicto Goal Despite EU Setback and Bispecific Competition

on

Isomorphic Labs, DeepMind Spinoff, Nears Human Trials for AI-Designed Drugs

on

AbbVie Enters Competitive RAS Oncology Field with $1.45B Biobucks Deal for Kestrel Option

on

Novartis CEO on Continued Evaluation of In Vivo CAR-T Therapies Without Current Deals

on

FDA Proposes to Withdraw Approval of Amgen's Tavneos Over Data Manipulation and Safety Issues

on

Profluent and Eli Lilly Announce $2.25 Billion Partnership for AI-Designed Genetic Medicines

on

CorMedix and Mundipharma Advance Rezzayo Expansion with Positive Phase III ReSPECT Trial Results

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Compass Therapeutics Stock Plummets After Mixed Trial Data in Biliary Tract Cancer Study

on

Xpress Wellness Appoints Joe Willey as Chief Operating Officer

on

UC Berkeley Startup Develops Jumping Genes Gene Therapy for Sustained GLP-1 Weight Loss

on

Oruka Therapeutics Announces Strong Phase 2a Results for ORKA-001 in Plaque Psoriasis, Outperforming Skyrizi

on

Erasca and Revolution Medicines Clash Over RAS Patent Infringement for ERAS-0015

on

EKF Diagnostics Holdings Appoints New CFO Helen Jones

on

agilon health Appoints Tim O’Rourke as Chief Executive Officer

on

Dyno Therapeutics to Present New Capsids and AI Advancements at 29th ASGCT Annual Meeting

on

Ligand to Acquire XOMA Royalty for $739 Million, Accelerating Profit Growth

on

Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR

on

Intellia Therapeutics Advances In Vivo CRISPR Therapy Lonvo-z to FDA After Positive Phase 3 HAELO Trial Results

on

Eli Lilly Acquires Ajax Therapeutics for $2.3B to Advance Next-Generation JAK Inhibitor

on

No Recent News on Thermo Fisher Scientific Selling Microbiology Business for $1B

on

Sun Pharma Strikes Biopharma's Largest Deal of 2026 with $11.75B Buyout of Organon

on

Veradermics Announces Topline Results Conference for Phase 2/3 VDPHL01 Oral Minoxidil Trial in Male Pattern Hair Loss

on

Lessons from the Eye: Stem Cell Therapies Advancing Regenerative Medicine

on

FDA Grants Priority Vouchers to Compass Pathways, Transcend Therapeutics, and Usona Institute for Psychedelic Therapies

on

Merck KGaA AGM: Kai Beckmann Appointed CEO Effective May 1, 2026

on

Taking the Guesswork out of Drug Development for Chagas Disease: Recent Advances in Computational Protocols and Clinical Collaborations

on

Astellas Pharma Top Management Personnel Changes (October 2025)

on

Amneal Inks $1.1B Kashiv Buyout to Pursue Biosimilar Market Leadership

on

Cityblock Health Appoints Dr. Alexander Billioux as New Chief Health Officer

on

Sanofi CFO Defends Hudson's Dupixent Legacy While Acknowledging R&D Setbacks

on

Daiichi Sankyo Postpones FY2026 Earnings Announcement to May 11, Shares Plunge 10%

on

Sanofi's Tolebrutinib Receives EMA Backing for Nonrelapsing Progressive MS Despite FDA Rejection

on

Avalyn Pharma Aims for $182M IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs

on